Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 569-578

  Alhariri, Moayad ^a   Omri, Abdelwahab ^a  

^a LAURENTIAN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; BISMUTH; CHITINASE; DIMERCAPTOETHANE; INTERLEUKIN 8; LIPOSOME; N ACYLHOMOSERINE LACTONE; PROTEINASE; THIOL DERIVATIVE; TOBRAMYCIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BIOSENSOR; CONTROLLED STUDY; DRUG EFFICACY; HORMONE RELEASE; IN VIVO STUDY; KIDNEY; LUNG; LUNG INFECTION; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; RAT; SPECTROPHOTOMETRY;

ACYL-BUTYROLACTONES; ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BISMUTH; DRUG COMPOUNDING; KIDNEY; LIPOSOMES; LUNG; MERCAPTOETHANOL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; RATS; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; VIRULENCE FACTORS;

EID: 84872012974     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01634-12     Document Type: Article

References (79)

1. Flume PA. 2009. Pulmonary complications of cystic fibrosis. Respir. Care 54:618-627.
2. O'Malley CA. 2009. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir. Care 54:641-657.
3. Sloane PA, Rowe SM. 2010. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr. Opin. Pulm. Med. 16:591-597.
4. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Lazarowski ER, Zhang L, Collins PL, Pickles RJ, Fredberg JJ, Boucher RC. 2005. Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J. Biol. Chem. 280:35751-35759.
5. Kukavica-Ibrulj I, Levesque RC. 2008. Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. Lab. Anim. 42:389-412.
6. Stutts MJ, Rossier BC, Boucher RC. 1997. Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J. Biol. Chem. 272:14037-14040.
7. Cardines R, Giufre M, Pompilio A, Fiscarelli E, Ricciotti G, Bonaventura GD, Cerquetti M. 2012. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int. J. Med. Microbiol. 302:45-52.
8. Lipuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323.
9. Yagci S, Hascelik G, Dogru D, Ozcelik U, Sener B. 28 November 2011. Prevalence and genetic diversity of Staphylococcus aureus small-colony variants in cystic fibrosis patients. Clin. Microbiol. Infect. [Epub ahead of print.] doi:10.1111/j.1469-0691.2011.03742.x.
10. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34:91-100.
11. Rao J, Damron FH, Basler M, Digiandomenico A, Sherman NE, Fox JW, Mekalanos JJ, Goldberg JB. 2011. Comparisons of two proteomic analyses of non-mucoid and mucoid Pseudomonas aeruginosa clinical isolates from a cystic fibrosis patient. Front. Microbiol. 2:162. doi:10.3389/fmicb.2011.00162.
12. Romling U, Wingender J, Muller H, Tummler B. 1994. A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl. Environ. Microbiol. 60:1734-1738.
13. Saiman L. 2011. Infection prevention and control in cystic fibrosis. Curr. Opin. Infect. Dis. 24:390-395.
14. Bryan R, Kube D, Perez A, Davis P, Prince A. 1998. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am. J. Respir. Cell Mol. Biol. 19:269-277.
15. Giltner CL, van Schaik EJ, Audette GF, Kao D, Hodges RS, Hassett DJ, Irvin RT. 2006. The Pseudomonas aeruginosa type IV pilin receptor binding domain functions as an adhesin for both biotic and abiotic surfaces. Mol. Microbiol. 59:1083-1096.
16. Lillehoj EP, Kim BT, Kim KC. 2002. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:L751-L756.
17. Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. 1998. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. Am. J. Respir. Cell Mol. Biol. 19:853-866.
18. Fothergill JL, Panagea S, Hart CA, Walshaw MJ, Pitt TL, Winstanley C. 2007. Widespread pyocyanin over-production among isolates of a cystic fibrosis epidemic strain. BMC Microbiol. 7:45. doi:10.1186/1471-2180-7-45.
19. Li LL, Malone JE, Iglewski BH. 2007. Regulation of the Pseudomonas aeruginosa quorum-sensing regulator VqsR. J. Bacteriol. 189:4367-4374.
20. Shrout JD, Tolker-Nielsen T, Givskov M, Parsek MR. 2011. The contribution of cell-cell signaling and motility to bacterial biofilm formation. MRS Bull. 36:367-373.
21. Nelson LK, D'Amours GH, Sproule-Willoughby KM, Morck DW, Ceri H. 2009. Pseudomonas aeruginosa las and rhl quorum-sensing systems are important for infection and inflammation in a rat prostatitis model. Microbiology 155:2612-2619.
22. Bjarnsholt T, Jensen PO, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT, Tolker-Nielsen T, Givskov M, Hoiby N, Ciofu O. 2010. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One 5: e10115. doi:10.1371/journal.pone.0010115.
23. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N, Schembri MA, Song Z, Kristoffersen P, Manefield M, Costerton JW, Molin S, Eberl L, Steinberg P, Kjelleberg S, Hoiby N, Givskov M. 2003. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22:3803-3815.
24. Schuster M, Lostroh CP, Ogi T, Greenberg EP. 2003. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol. 185:2066-2079.
25. Folders J, Algra J, Roelofs MS, van Loon LC, Tommassen J, Bitter W. 2001. Characterization of Pseudomonas aeruginosa chitinase, a gradually secreted protein. J. Bacteriol. 183:7044-7052.
26. Heurlier K, Williams F, Heeb S, Dormond C, Pessi G, Singer D, Camara M, Williams P, Haas D. 2004. Positive control of swarming, rhamnolipid synthesis, and lipase production by the posttranscriptional RsmA/RsmZ system in Pseudomonas aeruginosa PAO1. J. Bacteriol. 186:2936-2945.
27. Kay E, Humair B, Denervaud V, Riedel K, Spahr S, Eberl L, Valverde C, Haas D. 2006. Two GacA-dependent small RNAs modulate the quorum-sensing response in Pseudomonas aeruginosa. J. Bacteriol. 188:6026-6033.
28. Nouwens AS, Beatson SA, Whitchurch CB, Walsh BJ, Schweizer HP, Mattick JS, Cordwell SJ. 2003. Proteome analysis of extracellular proteins regulated by the las and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1. Microbiology 149:1311-1322.
29. Winson MK, Camara M, Latifi A, Foglino M, Chhabra SR, Daykin M, Bally M, Chapon V, Salmond GP, Bycroft BW, et al. 1995. Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 92:9427-9431.
30. Buchanan PJ, Ernst RK, Elborn JS, Schock B. 2009. Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem. Soc. Trans. 37:863-867.
31. Gomez MI, Prince A. 2008. Airway epithelial cell signaling in response to bacterial pathogens. Pediatr. Pulmonol. 43:11-19.
32. Geller DE, Rubin BK. 2009. Respiratory care and cystic fibrosis. Respir. Care 54:796-800.
33. Ratjen F, Brockhaus F, Angyalosi G. 2009. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cyst. Fibros. 8:361-369.
34. Adeboyeku D, Jones AL, Hodson ME. 2011. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J. Cyst. Fibros. 10:25-30.
35. Ramsey BW. 1996. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 335:179-188.
36. Babic F, Venturi V, Maravic-Vlahovicek G. 2010. Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in a Pseudomonas aeruginosa environmental isolate. BMC Infect. Dis. 10:148. doi:10.1186/1471-2334-10-148.
37. Garske LA, Beatson SA, Leech AJ, Walsh SL, Bell SC. 2004. Subinhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa. Pathology 36:571-575.
38. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39:34-39.
39. Khan W, Bernier SP, Kuchma SL, Hammond JH, Hasan F, O'Toole GA. 2010. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int. Microbiol. 13:207-212.
40. Prayle A, Smyth AR. 2010. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr. Opin. Pulm. Med. 16:604-610.
41. Zhang L, Mah TF. 2008. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J. Bacteriol. 190:4447-4452.
42. Stratton CW, Warner RR, Coudron PE, Lilly NA. 1999. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. J. Antimicrob. Chemother. 43:659-666.
43. Domenico P, Salo RJ, Novick SG, Schoch PE, Van Horn K, Cunha BA. 1997. Enhancement of bismuth antibacterial activity with lipophilic thiol chelators. Antimicrob. Agents Chemother. 41:1697-1703.
44. Huang CT, Stewart PS. 1999. Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J. Antimicrob. Chemother. 44:601-605.
45. Domenico P, O'Leary R, Cunha BA. 1992. Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 11:170-175.
46. Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. 2003. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J. Antimicrob. Chemother. 52:915-919.
47. Wu CL, Domenico P, Hassett DJ, Beveridge TJ, Hauser AR, Kazzaz JA. 2002. Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. Am. J. Respir. Cell Mol. Biol. 26:731-738.
48. Alipour M, Suntres ZE, Omri A. 2009. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64:317-325.
49. Fanciullino R, Ciccolini J. 2009. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr. Med. Chem. 16:4361-4371.
50. Willis L, Hayes D, Jr, Mansour HM. 2011. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 190:251-262.
51. Bailey MM, Berkland CJ. 2009. Nanoparticle formulations in pulmonary drug delivery. Med. Res. Rev. 29:196-212.
52. Halwani M, Blomme S, Suntres ZE, Alipour M, Azghani AO, Kumar A, Omri A. 2008. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm. 358:278-284.
53. Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A. 2009. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 373:141-146.
54. McLean RJ, Pierson LS, III, Fuqua C. 2004. A simple screening protocol for the identification of quorum signal antagonists. J. Microbiol. Methods 58:351-360.
55. Zhu H, Thuruthyil SJ, Willcox MD. 2002. Determination of quorum-sensing signal molecules and virulence factors of Pseudomonas aeruginosa isolates from contact lens-induced microbial keratitis. J. Med. Microbiol. 51:1063-1070.
56. Miller JH. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
57. Cash HA, Woods DE, McCullough B, Johanson WG, Jr, Bass JA. 1979. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 119:453-459.
58. Omri A, Beaulac C, Bouhajib M, Montplaisir S, Sharkawi M, Lagace J. 1994. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1090-1095.
59. Ratjen F, Munck A, Kho P, Angyalosi G. 2010. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65:286-291.
60. Alipour M, Halwani M, Omri A, Suntres ZE. 2008. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 355:293-298.
61. Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. 2007. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J. Antimicrob. Chemother. 60:760-769.
62. Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. 2011. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 16:295-300.
63. Alipour M, Dorval C, Suntres ZE, Omri A. 2011. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J. Pharm. Pharmacol. 63:999-1007.
64. Woo JK, Choi DS, Tran HT, Gilbert BE, Hong WK, Lee HY. 2009. Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 2:361-369.
65. Bi R, Shao W, Wang Q, Zhang N. 2008. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J. Drug Target. 16:639-648.
66. Marier JF, Brazier JL, Lavigne J, Ducharme MP. 2003. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J. Antimicrob. Chemother. 52:247-252.
67. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, Reimer DC, Pozharov VP, Minko T. 2009. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. 26:382-394.
68. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61:859-868.
69. Mugabe C, Azghani AO, Omri A. 2006. Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int. J. Pharm. 307:244-250.
70. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. 2004. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim. Biophys. Acta 1661:47-60.
71. Demaeyer P, Akodad EM, Gravet E, Schietecat P, Van Vooren JP, Drowart A, Yernault JC, Legros FJ. 1993. Disposition of liposomal gentamicin following intrabronchial administration in rabbits. J. Microencapsul. 10:77-88.
72. Horrevorts AM, Driessen OM, Michel MF, Kerrebijn KF. 1988. Pharmacokinetics of antimicrobial drugs in cystic fibrosis: aminoglycoside antibiotics. Chest 94:120S-125S.
73. Beaulac C, Clement-Major S, Hawari J, Lagace J. 1996. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 40:665-669.
74. Omri A, Suntres ZE, Shek PN. 2002. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 64:1407-1413.
75. Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. 2008. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv. Ther. 25:1019-1030.
76. Goscinski G, Lipcsey M, Eriksson M, Larsson A, Tano E, Sjolin J. 2004. Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock. Crit. Care 8:R35-R41.
77. Cantin A, Woods DE. 1993. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J. Clin. Invest. 91:38-45.
78. Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, Godschalk RW, van Schooten FJ. 2010. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis 25:149-154.
79. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. 2002. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57:759-764.